Abstract
Neuropathic pain is a phenomenon characterized by a high population prevalence by possessing several etiologies. In contrast to nociceptive pain, painful signals in neuropathic pain are originated in the nervous system, present poor responses to conventional treatments and may worsen the quality of life. Antiepileptic drugs are increasingly used for different purposes including migraine, neuropathic pain, tremor or psychiatric disorders and they have started to be called neuromodulators. These drugs may act on very different targets such as sodium, potassium or calcium channels, purinergic, GABAergic, glutamatergic or vanilloid receptors and different cytokines including IL-6 or TNF, each if which may be important in managing some aspects of neuropathic pain. Antiepileptic drugs have demonstrated effectiveness in the treatment of this pathology, and owing to the important development of these drugs in the last years, they may become a very effective tool. On the other hand, the increasing knowledge of the pathophysiology of nociception is leading to new channels and receptors as potential targets for treatment. In this paper we try to review the different potential therapeutic targets and role of antiepileptic drugs in the treatment of this pathology.
Keywords: Antiepileptic, neuromodulator, neuropathic pain, gabapentin pregabalin, topiramate, zonisamide, oxcarbacepine
CNS & Neurological Disorders - Drug Targets
Title: Neuromodulators and Therapeutic Targets in Neuropathic Pain: From Molecules to Man
Volume: 8 Issue: 3
Author(s): P. E. Bermejo and B. Anciones
Affiliation:
Keywords: Antiepileptic, neuromodulator, neuropathic pain, gabapentin pregabalin, topiramate, zonisamide, oxcarbacepine
Abstract: Neuropathic pain is a phenomenon characterized by a high population prevalence by possessing several etiologies. In contrast to nociceptive pain, painful signals in neuropathic pain are originated in the nervous system, present poor responses to conventional treatments and may worsen the quality of life. Antiepileptic drugs are increasingly used for different purposes including migraine, neuropathic pain, tremor or psychiatric disorders and they have started to be called neuromodulators. These drugs may act on very different targets such as sodium, potassium or calcium channels, purinergic, GABAergic, glutamatergic or vanilloid receptors and different cytokines including IL-6 or TNF, each if which may be important in managing some aspects of neuropathic pain. Antiepileptic drugs have demonstrated effectiveness in the treatment of this pathology, and owing to the important development of these drugs in the last years, they may become a very effective tool. On the other hand, the increasing knowledge of the pathophysiology of nociception is leading to new channels and receptors as potential targets for treatment. In this paper we try to review the different potential therapeutic targets and role of antiepileptic drugs in the treatment of this pathology.
Export Options
About this article
Cite this article as:
Bermejo E. P. and Anciones B., Neuromodulators and Therapeutic Targets in Neuropathic Pain: From Molecules to Man, CNS & Neurological Disorders - Drug Targets 2009; 8 (3) . https://dx.doi.org/10.2174/187152709788680661
DOI https://dx.doi.org/10.2174/187152709788680661 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Herbal Compounds with Special Reference to Gastrodin as Potential Therapeutic Agents for Microglia Mediated Neuroinflammation
Current Medicinal Chemistry Astroglial Connexins in Neurological and Neuropsychological Disorders and Radiation Exposure
Current Medicinal Chemistry PDZ Domains at Excitatory Synapses: Potential Molecular Targets for Persistent Pain Treatment
Current Neuropharmacology Polyphenols as Potential Therapeutics for Pain and Inflammation in Spinal Cord Injury
Current Molecular Pharmacology Preparation and Characterization of Rivastigmine Loaded Human Serum Albumin (HSA) Nanoparticles
Current Drug Delivery Scopolamine and Depression: A Role for Muscarinic Antagonism?
CNS & Neurological Disorders - Drug Targets Molecular Docking, Synthesis and CNS Activity of Some Novel 1, 4-Benzodiazepine Derivatives
Letters in Drug Design & Discovery Diabetes Mellitus: Channeling Care through Cellular Discovery
Current Neurovascular Research Diagnosing and Treating Depression in Older and Oldest Old
Current Pharmaceutical Design Development and Validation of 'Level A' In Vitro - In Vivo Correlation for Extended Release Tablets of Lamotrigine
Current Bioactive Compounds Integrating Virtual Screening Methods to the Quest for Novel Membrane Protein Ligands
Current Medicinal Chemistry - Central Nervous System Agents In Vivo Experimental Models of Epilepsy
Central Nervous System Agents in Medicinal Chemistry Transglutaminase Inhibition as a Possible Therapeutical Approach to Protect Cells from Death in Neurodegenerative Diseases
Recent Patents on CNS Drug Discovery (Discontinued) Computational Protein-Protein Docking Reveals the Therapeutic Potential of Kunitz-type Venom against hKv1.2 Binding Sites
CNS & Neurological Disorders - Drug Targets From the Molecular Mechanism to Pre-clinical Results: Anti-epileptic Effects of Fingolimod
Current Neuropharmacology Metformin: Repurposing Opportunities for Cognitive and Mood Dysfunction
CNS & Neurological Disorders - Drug Targets Astrocyte`s RAGE: More Than Just a Question of Mood
Central Nervous System Agents in Medicinal Chemistry Navigating the Sea Changes in Patent Law to Successfully Build Value
Technology Transfer and Entrepreneurship (Discontinued) Reducing Gabaergic Inhibition Restores Cognitive Functions in a Mouse Model of Down Syndrome
CNS & Neurological Disorders - Drug Targets <i>Rhanterium suaveolens</i>, Vitamin E and C Pretreatment Prevents Valproic Acid Induced Renal Oxidant Damage
The Natural Products Journal